---

2026

• Hepatitis B virus protein X promotes survival and loss of hepatocyte identity in a differentiated human liver organoid system

• HIV associated immune aging among people living with HIV: implications for long-term antiretroviral therapy and potential HIV cure interventions in sub-Saharan Africa

• HIV-1 reservoir inducibility and immune phenotypes after prolonged analytical treatment interruption: a long-term follow-up study

• Persistent immune dysfunction during suppressive antiretroviral therapy: implications for analytical treatment interruption trials for chronic HIV infections in sub-Saharan Africa

• Tools to Quantify and Characterize the Persistent Reservoir in People with HIV-1: Focus on Non-B Subtypes

• HIV-specific CD8+ T-cell proliferative response 24 weeks after early antiretroviral therapy initiation is associated with the subsequent reduction in the viral reservoir

• IBA-1⁺CD68⁺ Germinal Center Macrophages Harbor Proviral and Inducible Clade C HIV Reservoirs in ART-Suppressed Human Lymph Nodes

2025

• Targeting HIV-1 transcription: road to a cure?

• Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

• HIV cure research contributions from Africa in the last three decades

• Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets.

• Cost-reduction strategy to culture patient derived bladder tumor organoids

2024

• Development of a latency model for HIV-1 subtype C and the impact of long terminal repeat element genetic variation on latency reversal

• Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy

• Molecular biomarkers of progression in non-muscle-invasive bladder cancer – beyond conventional risk stratification

• Specific quantification of inducible HIV-1 reservoir by RT-LAMP

• A 3D organoid platform that supports liver-stage P.falciparum infection can be used to identify intrahepatic antimalarial drugs

• NPEPPS Is a Druggable Driver of Platinum Resistance

• PCID2 dysregulates transcription and viral RNA processing to promote HIV-1 latency

2023

• Hepatitis C virus infects and perturbs liver stem cells

• The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review

• Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin

• The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy

2022

• Ten decadal advances in fungal biology leading towards human well-being

• HibeRNAtion: HIV-1 RNA Metabolism and Viral Latency

• DEAD-ly Affairs: The Roles of DEAD-Box Proteins on HIV-1 Viral RNA Metabolism

• Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents

• Production of Recombinant Hepatitis B virus (HBV) and Detection of HBV in Infected Human Liver Organoids

• Generation, Maintenance and HBV Infection of Human Liver Organoids

2021

• A Two-Color Haploid Genetic Screen Identifies Novel Host Factors Involved in HIV-1 Latency

• Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

• Evolution of organoid technology: Lessons learnt in Co-Culture systems from developmental biology

• Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models

• 3D human liver organoids: An in vitro platform to investigate HBV infection, replication and liver tumorigenesis

• Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir

2020

• Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA

• Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency

• Towards the next step: LoViRet patients for HIV-1 cure studies

• Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1

2019

• A broad drug arsenal to attack a strenuous latent HIV reservoir

• T cell toxicity of HIV latency reversing agents

2018

• Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal

• A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other “Shock” Drugs

• Allele-specific long-distance regulation dictates IL-32 isoform switching and mediates susceptibility to HIV-1

• Transcription: Insights From the HIV-1 Promoter

2016

• Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal

2014

• HIV eradication: combinatorial approaches to activate latent viruses

2013

• HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages

• Wnt signaling regulates the lineage differentiation potential of mouse embryonic stem cells through Tcf3 down-regulation

• Znf202 affects high density lipoprotein cholesterol levels and promotes hepatosteatosis in hyperlipidemic mice

2012

• Epigenetic regulation of B lymphocyte differentiation, transdifferentiation, and reprogramming

• The BAF complex and HIV latency

2011

• Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency